IVRS launches a new segment model on Human Glioblastoma!
We are excited to launch our new orthotopic model of human glioblastoma. We use cutting-edge technology such as patient-derived xenografts (PDX) and in vivo bioluminescence
Let’s discuss how we can accelerate your preclinical phase!
Save time
Save time by collecting data at each step of your experiment.
Reduce costs
High-throughput approaches and capacity to follow up single animals.
Real-time visuals
Follow the disease progression in real time from day 0.
In vivo imaging plays a pivotal role in monitoring individual variations in real-time to design safer and more effective therapies.
Explore how our advanced in vivo imaging technology can enhance your capabilities.
100+ completed projects
20+ years of experience
10+ global partners
Several international scientific publications
Discover our cutting-edge segment models, meticulously crafted at our company to unlock the power of drug discovery and ensure rigorous and efficient preclinical testing in the development of more effective treatments.
We are excited to launch our new orthotopic model of human glioblastoma. We use cutting-edge technology such as patient-derived xenografts (PDX) and in vivo bioluminescence
IVRS was recently appointed as industry winners or ‘’Branschvinnare’’, which is awarded to Swedish companies who have reached exceedingly positive revenue and result changes during the
We constantly work to develop clinically relevant models to provide reliable platforms for preclinical drug validation. Today, we are thrilled to announce the launch of
Do you want to learn more about our work and how we can help you?
Visit us